Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB25FDL92
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $122,843
Award facts
- Contract value 100% obligated
- $122,843.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $122,843.40 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on September 17, 2025, for Keytruda 100 mg/4 mL vials. The award carries no set-aside designation and is scheduled for completion by October 8, 2025, with performance at the contractor's Park Ridge facility. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million through November 2026, which authorizes the issuance of firm fixed-price orders for pharmaceutical products supporting military healthcare facilities worldwide.
Keytruda (pembrolizumab) is a checkpoint inhibitor immunotherapy used in oncology treatments, reflecting DMS Pharmaceutical Group's established role as a critical supplier in the federal pharmaceutical supply chain. The contractor's contract portfolio demonstrates consistent success in securing pharmaceutical delivery orders across multiple therapeutic categories, including specialty medications, biologics, and controlled substances. As a GSA-registered small business since 2001, DMS Pharmaceutical Group has leveraged its woman-owned designation to compete effectively in federal procurement while maintaining a robust distribution network serving Department of Defense medical facilities.
Quick answers
Who was awarded contract SPE2DB25FDL92?
SPE2DB25FDL92 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 17, 2025.
How much is contract SPE2DB25FDL92 worth?
The government has obligated $122,843 on SPE2DB25FDL92.
Is contract SPE2DB25FDL92 an order under another contract?
Yes. SPE2DB25FDL92 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDL92 competed?
The extent of competition for SPE2DB25FDL92 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award